Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Non-Current Assets (2022 - 2025)

Historic Non-Current Assets for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $38.9 million.

  • Zentalis Pharmaceuticals' Non-Current Assets fell 2270.84% to $38.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $164.5 million, marking a year-over-year decrease of 2208.88%. This contributed to the annual value of $44.3 million for FY2024, which is 1946.33% down from last year.
  • Latest data reveals that Zentalis Pharmaceuticals reported Non-Current Assets of $38.9 million as of Q3 2025, which was down 2270.84% from $40.1 million recorded in Q2 2025.
  • Zentalis Pharmaceuticals' 5-year Non-Current Assets high stood at $104.4 million for Q1 2022, and its period low was $38.9 million during Q3 2025.
  • Over the past 4 years, Zentalis Pharmaceuticals' median Non-Current Assets value was $55.0 million (recorded in 2023), while the average stood at $63.8 million.
  • As far as peak fluctuations go, Zentalis Pharmaceuticals' Non-Current Assets plummeted by 4261.7% in 2023, and later tumbled by 947.75% in 2024.
  • Quarter analysis of 4 years shows Zentalis Pharmaceuticals' Non-Current Assets stood at $87.4 million in 2022, then crashed by 37.09% to $55.0 million in 2023, then decreased by 19.46% to $44.3 million in 2024, then dropped by 12.02% to $38.9 million in 2025.
  • Its last three reported values are $38.9 million in Q3 2025, $40.1 million for Q2 2025, and $41.1 million during Q1 2025.